AB-SA01 is a 3-phage investigational therapeutic being developed for treatment of MDR S. aureus infections. In preclinical studies, AB-SA01 demonstrated broad activity against more than 96% of global S. aureus MDR clinical isolates. AB-SA01 has previously completed two Phase 1 studies, one as a topical administration in healthy volunteers, and the other in patients with chronic rhinosinusitis (CRS) infections. AmpliPhi received positive feedback from a Type B meeting with FDA in Q1 2017. Additional target indications include bacteremia, endocarditis (including prosthetic valve), prosthetic joint infections, osteomyelitis, diabetic foot ulcers, and others. AB-SA01 is manufactured in a cGMP-certified facility dedicated to producing bacteriophage products for human use.